Background: This phase I study was designed to determine the maximum tolerated dose (MTD) and preliminary efficacy of docetaxel with concurrent radiotherapy (RT), in high-risk squamous cell carcinoma of the head and neck. Patients and Methods: Eligible patients had resected squamous cell carcinoma of the head and neck, histologically involved lymph nodes, and/or extranodal disease, and/or involved surgical margins and performance status 0 to 1. Treatment included weekly docetaxel with concurrent RT in a dose-finding study; a subsequent small cohort of patients was treated using the MTD of docetaxel. Results: Twenty patients were enrolled. Planned accrual was 25, but the study was closed prematurely because of slow accrual. The MTD was 15 mg/m 2 . Dose-limiting toxicity was oral stomatitis. Therapy was well tolerated. Five patients experienced locoregional relapse at a median follow-up of 32 months. Conclusion: Docetaxel with concurrent RT has acceptable toxicity. This approach warrants further investigation in a phase II trial.
S quamous cell carcinoma of the head and neck comprises 2% to 3% of all cancers in the United States and accounts for 1% to 2% of all cancer deaths. 1 Prognosis correlates strongly with stage at diagnosis. Survival for stage I disease exceeds 80%; however, for patients with locally advanced disease at the time of diagnosis, specifically stage III and IV, survival drops to below 40%. 2 Development of nodal metastasis reduces survival of a small primary tumor by approximately 50%. Involvement of even a single lymph node is associated with a marked decline in survival. Other high-risk features include extracapsular extension of nodal disease and positive surgical margins. 3 The standard of care for high-risk squamous cell carcinoma of the head and neck (HNSCC) includes postoperative chemoradiotherapy usually with cisplatin for patients who have high-risk features after resection. 4, 5 This approach, however, is not without significant toxicity. In an effort to devise a less toxic strategy, we investigated the use of weekly docetaxel with concurrent radiotherapy in patients with high-risk HNSCC. The primary end points of this phase I study were to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of weekly administered docetaxel, concurrently with radiation in the adjuvant setting. We intended to expand this study to a phase II trial, using the MTD, with endpoints, including an assessment of locoregional relapse, patterns of first relapse, disease-free survival, and overall survival; however, the study was terminated early because of slow accrual.
MATERIALS AND METHODS
Patients with histologically proven and completely resected squamous cell carcinoma of the oral cavity, oropharynx, or larynx, with histologically involved regional lymph nodes and/or extra nodal disease and/or positive surgical margins were eligible to participate. Other inclusion criteria included the following: a Southwest Oncology Group performance status, (SWOG PS) of 0 or 1, age Ն18 years, absolute neutrophil count Ն1500/mm 3 , hemoglobin Ͼ8.0 g/dL, platelet count Ն100,000/dL, and adequate renal and liver function. Patients were required to register within 6 weeks of surgery, by signed and witnessed informed consent, describing the investigational nature of this study. Patients who had prior chemotherapy or radiation therapy to the head and neck, evidence of distant metastasis, synchronous or concurrent head and neck primary tumors, peripheral neuropathy greater than grade 1, or other malignancies within the last 5 years were excluded. This study was approved by the institutional review boards of each participating institution and informed consent was obtained from each subject.
Treatment Plan
In the phase I portion of the study, a traditional dose escalation schema was planned, evaluating cohorts of 6 patients each, starting with docetaxel at a weekly dose of 20 mg/m 2 for 6 weeks, administered concurrently with radiation therapy in the postoperative setting. DLT was defined as any grade 4 neutropenia lasting for more than 3 days, grade 4 neutropenia with fever, grade 4 thrombocytopenia, grade 4 stomatitis, or any other grade 3 or 4 nonhematologic toxicity. Toxicities were graded according to NCI CT-CAE v 3.0. Because of higher than expected DLT observed at the initial dose level, a dose de-escalation schema was designed such that the next cohort was to be treated with 15 mg/m 2 /week of docetaxel concurrent with radiation therapy. Subsequent cohorts were to be treated at progressively lower doses of docetaxel, decreased by 5 mg/m 2 /week until the MTD was reached, defined as the maximum dose level of docetaxel tolerated such that no more than 2 of 6 patients in the cohort experienced DLT. The phase II portion of the trial was then designed to use this MTD of weekly docetaxel in combination with daily radiation therapy in a total of 25 patients with high-risk HNSCC.
A 25% dose reduction in subsequent doses of docetaxel occurred if patients experienced any one of the DLTs described above, or grade 2 peripheral neuropathy, or liver dysfunction defined as total bilirubin, alkaline phosphatase, or aspartate transaminase/ alanine transaminase Ͼ5 institutional upper limit of normal.
For grade 4 toxicity, docetaxel was to be held for 7 days, and a 25% dose reduction was recommended for subsequent doses. No more than 2 dose reductions were allowed for any given patient. If a patient required a third dose reduction, they were to be removed from the study treatment. Patients were also removed from study if they required more than 3 weeks of delay in their treatment secondary to toxicity. All dose reductions were to remain permanent throughout the remainder of the planned concurrent therapy.
The radiation therapy consisted of 60 Gy in 30 fractions over 6 weeks. In all patients, radiation therapy was planned and delivered with three-dimensional conformal radiation therapy technique. A minimum of 54 Gy was delivered to low-risk sites (eg, areas requiring radiation that were distant from the region that rendered patient high risk). A conedown boost of up to 6 Gy delivered in 3 fractions over 3 days was allowed at the discretion of the treating radiation oncologist to the high-risk site(s) only. Radiotherapy was started as soon as adequate healing after surgery had been established, but no longer than 6 weeks after surgery. Daily dose reductions to 1.8 Gy were allowed if a treatment break due to toxicity became necessary.
Statistical Methods
Rules for accrual to the phase I portion of the trial are described above. The phase II portion of the trial was designed, as described, to use the MTD of weekly docetaxel in combination with daily radiation therapy in a total of 25 patients with high-risk HNSCC. Because of slow accrual the study was closed early. Conclusions in the phase II portion are therefore not possible. Conclusions on efficacy of this combination were based on 20 evaluable patients. Our original statistical design was followed such that, if less than 3 patients developed locoregional recurrence at 2 years, we would conclude that the recurrence rate in this patient population is highly likely, with 95% confidence, to be less than 33%. If 3 to 7 patients developed locoregional recurrence at 2 years and if the toxicity/feasibility profile appeared acceptable, interest in this drug would be maintained such that further investigation would be considered. If 8 or more patients developed locoregional recurrence at 2 years, we would conclude that this recurrence rate is likely, with 95% confidence, to be greater than 23% (that observed with cisplatin/RT) and could be as high as 33%. Based on these findings, we would conclude that further investigation of this therapy in this particular patient population would not be warranted.
Descriptive statistics were used to detail the characteristics of the study sample, toxicity profile, and patterns of relapse. Diseasefree and overall survival were estimated using Kaplan-Meier methods. Time was calculated from the date of study enrollment to the date of first recurrence or death for disease-free and overall survival, respectively. Patients with no event were censored at the last follow-up date with no recorded event.
RESULTS
Over a 3-year period, 20 patients were enrolled in this study. The characteristics of the entire study population are summarized in Table 1 . Testing for human papilloma virus was not performed. Five patients were enrolled in the initial cohort, using a dose of docetaxel of 20 mg/m 2 /week. A total of 15 patients were enrolled in the next dose de-escalation cohort and subsequent phase II portion of the trial. The median age was 60 years. Fourteen men and 6 women were enrolled. High-risk feature included positive margins, lymph node involvement, and extracapsular extension. Table 2 characterizes the high-risk feature and site of relapse in each study patient. 
Phase I Safety and Toxicity
Grade 3 and 4 toxicities of the phase I portion of the trial are summarized in Table 3 . In the first cohort, 4 of the first 5 treated patients suffered grade 4 oral stomatitis at 20 mg/m 2 /week of docetaxel. Each patient received all planned doses of chemotherapy and radiation therapy. All toxicities resolved within 2 to 3 weeks. No patients were gastrostomy tube dependent for nutrition or hydration beyond 8 weeks of completion of therapy. Based on the high rate of grade 4 oral stomatitis, it was decided to de-escalate the docetaxel dose and treat subsequent patients at 15 mg/m 2 per week.
The second cohort of 6 patients enrolled in the phase I portion of the trial experienced slightly less toxicity. Five of these 6 patients developed grade 3 oral stomatitis, which again resolved within 2 to 3 weeks of discontinuing treatment. Patient 7 developed grade 4 aspiration pneumonia with associated hypoxia, requiring hospitalization and intravenous antibiotics, but this was not felt to be treatment related. As a result, this patient missed his last scheduled dose of docetaxel but was discharged home after 2 days, with his baseline supplemental oxygen therapy and a course of oral antibiotics. Two patients at this dose level experienced grade 3 skin toxicity, defined as dry desquamation in the radiation field, which resolved within 1 to 2 weeks of completion of therapy. Two patients required a dose reduction in the fourth dose. Gastrostomy tube dependence resolved within 6 weeks of completing treatment for all patients. This dose level was therefore determined to be the MTD.
Nine more patients were treated at the MTD, 15 mg/m 2 /week docetaxel, as part of the planned phase II portion of the trial, before the study was closed because of poor accrual. Thirteen of all 15 patients treated at the MTD, (86.7%; 95% CI, 72.0 -97.6), experienced grade 3 stomatitis but not grade 4 stomatitis. In 1 patient, the last 2 doses were held because of stomatitis. All patients enrolled completed all planned radiation therapy. All remaining patients enrolled had their gastrostomy tubes removed within 3 to 6 weeks of completion of therapy. No significant myelosuppression, febrile neutropenia, nausea or vomiting, or peripheral neuropathy was observed. No treatment-related deaths occurred.
Relapse-Free Survival, Overall Survival, and Pattern of Relapse
Survival and relapse data are based on all 20 patients enrolled in the trial. Four of the initial 5 patients enrolled remained alive without relapse. With a median duration of follow-up of 32 months, 9 patients have relapsed (Table 4 ). Four patients relapsed locally, including 1 of 5 patients in the initial cohort, 1 relapsed locally and with distant metastases, 4 patients developed distant metastases alone. The probability of 1-year relapse-free survival (RFS) was 59.2% (95% CI, 37-81). Two-year RFS probability was 52.6% (95% CI, 30 -76). The mean RFS time was 32 months. Kaplan-Meier estimates of RFS are shown in Figure 1 . The median RFS has not yet been met. One-year overall survival probability is 94.4% (95% CI, 84 -100). Two-year overall survival probability is 69.3% (95% CI, 47-92) (Fig. 2) . The mean overall survival time is 41.6 months. The median overall survival has not yet been reached.
DISCUSSION
In 2004, Cooper et al, published the results of RTOG 9501, a large, randomized trial demonstrating that adding concurrent cisplatin to postoperative radiotherapy in high-risk patients with HNSCC yielded a reduction in local and regional recurrence, as well as improvement in disease-free survival over that of standard postoperative radiotherapy alone. 4 A similarly designed European trial revealed similar results and an overall survival advantage to the 1  49  Tonsil  1  2a  IVa  20  6  Grade 3 stomatitis  2 wk  2  26  Tongue  2  1  III  20  6  Grade 4 stomatitis  3 wk  3  47  Larynx  2  2b  IVa  20  7  Grade 4 stomatitis  3 concurrent therapy. 5 Based on these data, postoperative cisplatin administered every 21 days for 3 doses with concurrent radiotherapy became the standard of care in the United States for patients with high-risk resected HNSCC. Unfortunately, the benefit of postoperative concurrent chemoradiotherapy was not without significant toxicity. In RTOG 9501, grade III toxicity occurred in 77% of patients treated with concurrent radiation and cisplatin versus 34% of patients treated with radiation alone. 3 Most of the increase was due to mucositis, gastrointestinal, and hematologic toxicity. In an effort to obtain similar benefit but less toxicity, other agents warrant investigation in this setting.
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Docetaxel has proven to be effective against HNSCC as an induction therapy and in the treatment of metastatic disease. 6 -12 There is more limited experience incorporating docetaxel in the adjuvant setting, especially when combined with radiotherapy in the treatment of other malignancies. [13] [14] [15] A number of trials have shown 60.00 50.00 40.00 30.00 20.00 10.00 0.00 docetaxel to have radiosensitizing effects and manageable toxicity when administered weekly. 16 -18 In our pilot phase I/II trial, we observed that docetaxel with concurrent radiotherapy is well tolerated with manageable toxicity when administered in the postoperative setting to patients with high-risk HNSCC. Most of the toxicity that we observed was oral stomatitis; however, no grade 4 stomatitis was experienced at the 15 mg/m 2 /week dose level. In the phase I portion of the study, we concluded that 15 mg/m 2 /week of docetaxel was the MTD when administered concurrently with radiotherapy. The phase II portion of this trial could not be completed as planned, but reviewing the toxicity of all 15 of the patients treated at the MTD, we concluded that toxicity was manageable and appears efficacious, although with a very limited patient sample. The degree of stomatitis seen in our study was within the same range of the much larger RTOG study, suggesting that docetaxel with concurrent radiation is not any worse than cisplatin with radiation.
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CONCLUSION
We conclude that this dose and schedule of concurrent docetaxel and radiotherapy has acceptable toxicity and that preliminary efficacy data are promising; thus, further investigation in a larger phase II setting is warranted.
